Nature of the business and basis of preparation

BeyondSpring Inc. (the “Company”) was incorporated in the Cayman Islands on

November 21, 2014.

The Company and its subsidiaries (collectively, the “Group”) are principally engaged in clinical stage biopharmaceutical activities focused on the development of innovative cancer therapies. The Company is under the control of Mr. Linqing Jia and Dr. Lan Huang as a couple (collectively, the “Founders”) since its incorporation.

As at

March 31, 2019,

the subsidiaries of the Company are as follows:

Name of company	Place of incorporation	Date of incorporation		Percentage of ownership by the Company		Principal activities

BeyondSpring Pharmaceuticals Inc.	Delaware, United States of America (“U.S.”)		June 18, 2013		100%	Clinical trial activities

BeyondSpring Ltd.	The British Virgin Islands (“BVI”)		December 3, 2014		100%	Holding company

BeyondSpring (HK) Limited	Hong Kong		January 13, 2015		100%	Holding company

Wanchun Biotechnology Limited	BVI		April 1, 2015		100%	Holding company

Wanchun Biotechnology (Shenzhen) Ltd.	The People’s Republic of China (“PRC”)		April 23, 2015		100%	Holding company

Dalian Wanchunbulin Pharmaceuticals Ltd. (“Wanchunbulin”)	PRC		May 6, 2015		60%	Clinical trial activities

BeyondSpring Pharmaceuticals Australia PTY Ltd. (“BeyondSpring Australia”)	Australia		March 3, 2016		100%	Clinical trial activities

Beijing Wanchun Pharmaceutical Technology Ltd. (“Beijing Wanchun”)	PRC		May 21, 2018		60%	Clinical trial activities

The accompanying unaudited interim condensed consolidated balance sheet as of

March 31, 2019,

the unaudited interim condensed consolidated statements of comprehensive loss for the

three

months ended

March 31, 2018

and

2019,

the cash flows for the

three

months ended

March 31, 2018

and

2019,

and the related footnote disclosures are unaudited. These unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with U.S. GAAP for interim financial information using accounting policies that are consistent with those used in the preparation of the Company’s audited consolidated financial statements for the year ended

December 31, 2018.

Accordingly, these unaudited interim condensed consolidated financial statements do

not

include all of the information and footnotes required by U.S. GAAP for annual financial statements.

In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements contain all normal recurring adjustments necessary to present fairly the financial position, operating results and cash flows of the Group for each of the periods presented. The results of operations for the

three

months ended

March 31, 2019

are

not

necessarily indicative of results to be expected for any other interim period or for the full year of

2019.

The consolidated balance sheet as of

December 31, 2018

was derived from the audited consolidated financial statements at that date but does

not

include all of the disclosures required by U.S. GAAP for annual financial statements. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended

December 31, 2018.